Previous estimates of the utility of polygenic risk score analysis for the prediction of Alzheimer disease have given area under the curve (AUC) estimates of <80%. However, these have been based on the genetic analysis of clinical case-control series. Here, we apply the same analytic approaches to a pathological case-control series and show a predictive AUC of 84%. We suggest that this analysis has clinical utility and that there is limited room for further improvement using genetic data. ANN NEUROL 2017;82:311-314 P olygenic risk score (PRS) analysis enhances the predictability of the diagnosis of Alzheimer disease (AD) over the use of just the apolipoprotein E (APOE) locus.
tion, the majority of controls used in GWASs are sampled from a general population and are often underaged to develop AD. This diagnostic uncertainty has also been demonstrated by the observation of c9orf72 expansions (a locus causing frontotemporal dementia) within some of the clinical AD cohorts used in the generation of the GWAS and AD sequencing data. 3 Having a better understanding of the diagnostic utility of PRS is of importance for two reasons: first, because it enables the accurate assessment of how much risk for disease there is still left to be found, and this is important in setting research goals; and second, because this type of analysis could be used in the refinement of inclusion criteria for clinical trials and eventually in clinical health care recommendations.
We have previously reported a GWAS in clinically characterized and neuropathologically confirmed samples of AD and matched controls 4 : in this analysis, we apply PRS to these pathological data to determine whether some of the "missing heritability" of AD is due to clinical misdiagnosis.
Subjects and Methods
The sample characteristics of the dataset used in this study were the same as in our original analysis. This project was declared institutional review board exempt (Medstar Project #.2003-118) under the Code of Federal Regulations (45 CFR, 46). Eight cases and 8 controls had corrupted data files and were omitted. 4 This left 1,011 cases and 583 controls. The total number of imputed single nucleotide polymorphisms (SNPs) was 36,481,940. The number of SNPs with INFO score > 0.8 was 11,016,052. From these, the number of SNPs with minor allele frequency ! 0.01 was 7,868,100, and these were used in the analysis. Association analysis was performed for each SNP using logistic regression analysis as implemented in snptest. 5 We performed predictive modeling using polygenic score based upon SNPs with probability value cutoff p 5 10 24 , 10 23 , 0.01, 0,05, . . . 0.5 as in Lambert et al 6 as predictor variables. These sets of SNPs capture apolipoprotein E and index GWAS SNPs 6 either directly or via their proxies. For prediction modeling, we converted imputed "dosage" genotypes in our data to "most probable genotype" with probability > 90%. The individual polygenic risk scores were generated as sums of the risk alleles weighted by effect sizes as in the International Genomics of Alzheimer's Project (IGAP) study, 6 then were further adjusted for the first 10 principal components and standardized. The models were fitted using the abovementioned individual polygenic risk scores and predicting AD/control status in our study. This is the most powerful way of testing the prediction ability of the strongest genetic predictors to date; however, our study was part of the IGAP study 6 ($3% overlap), and therefore the results will be marginally overfitted. We accounted for this overfitting in our analysis as below.
Because summary statistics for the IGAP 6 data excluding our sample were not available to us, we estimated the effect of possible bias using simulations. For that, we first simulated a sample of 17,008 cases and 37,154 controls, matching the IGAP stage I study, for a typical SNP with minor allele frequency 5 0.2 and effect size of odds ratio (OR) 5 1.05. This OR matches the average effect size for IGAP pruned SNPs with association p 0.5, mean(B IGAP ) 5 0.05, mean(SE IGAP ) 5 0.035, and OR IGAP 5 exponential(0.05) 5 1.05. Then we randomly removed 1,101 cases and 583 controls (matching our study size) and recalculated the association effect size 1,000 times de novo. The "removal-based-simulated" effect sizes for a single typical SNP were found to be normally distributed, with mean B SIM 5 0.05 (SD SIM 5 0.004). Assuming that the removed sample is a random subset of cases and controls, the expected distribution of the IGAP pruned SNPs effect sizes should have the same mean but slightly increased standard error:
where N is the IGAP sample size and N o is the overlap sample size. In particular, we can roughly expect mean (SE IGAP ) ADJ 5 0.035/sqrt(0.97)50.0355, where 0.035 is the mean(SE IGAP ) of the effect size for IGAP pruned SNPs with association p 0.5.
To adjust prediction modeling for overlapping samples, we ran further simulations where the effect sizes for each SNP in the IGAP study were simulated as b $ N(B IGAP , SD 5 0.12 * SE IGAP ), where B IGAP is the beta-coefficient and SE IGAP is the standard error for that SNP in the IGAP study. Standard deviation (SD) 5 0.12 * SE IGAP was chosen empirically to allow for the variability due to the IGAP B-coefficient estimate and due to random subsample removal. As a rough example, multiplying the mean(SE IGAP ) ADJ by 0.12 results in an SD that approximately matches the "removal-based-simulated" SD SIM : 0.12 * mean(SE IGAP ) ADJ 5 0.12 * 0.0355 % 0.004 5 SD SIM . Thus, in each simulation step, each SNP in IGAP had a simulated effect size and probability value corresponding to this effect size. Then the SNPs were reselected and repruned, and the polygenic scores were recalculated. The prediction accuracy of the simulated PRS was calculated at each simulation (n 5 1,000 simulations), and the mean of the simulated AUC for SNPs with p 0.5 was reported and is discussed below.
Results
The primary results (QQ plot and Manhattan plot) were consistent with our previous analysis of these data. 4 There were no genome-wide significant hits apart from APOE locus. We compared the results of our analysis with 21 index genome-wide significant SNPs identified in the IGAP 6 study (Table 1) . Sixty-three percent of IGAP GWAS index SNPs (14 of 22) show larger effects in our dataset compared to the original report, 6 of which 5 have significantly larger effect sizes (see the last column of Table 1 ), including the 2 SNPs tagging the APOE status. The results of predictive modeling are presented in Table 2 . Training on the whole IGAP, the prediction accuracy AUC reaches 86% (Fig) when all SNPs with p 0.5 are included in the model. However, as discussed above, there is an element of overfitting in this analysis, as our data were part of the IGAP analysis. The polygenic risk scores were constructed using independent SNPs associated with AD in the International Genomics of Alzheimer's Project at different significance levels (Model column). As can be seen, the AUC reaches 0.847 when all SNPs with p < 0.05 are included in the mode (29,017 SNPs). Further relaxation of the probability values has very little effect on the AUC, while increasing the number of SNPs greatly. In all cases, 95% confidence intervals for the AUC were <0.03. a Number of SNPs participating in the predictive model. Accounting for this possible inflation using simulation (see Subjects and Methods), the prediction accuracy is 84% (95% confidence interval [CI] 5 82-86%).
Discussion
These data systematically confirm, in the context of genome-wide data, our results examining the APOE locus 4 : genetic prediction is better in the context of autopsy-confirmed cases and controls. This has implications for our view of how much genetic variability remains to be found; in an earlier analysis, we estimated that the theoretical maximal genetic variance to be found would generate an AUC of 82% (95% CI 5 78-85%). 7 The figure now identified, based on the genome-wide analysis of a pathological cohort, is 84% (95% CI 5 82-86%). Thus, the theoretical and assessed figures for risk prediction accuracy overlap, and both are larger than the AUC of 0.75 assessed using clinical cohorts. 1 There is thus further evidence that polygenic risk profiling captures the SNP heritability very well with regard to common variation in AD, although of course, heritability estimates 7 were constructed on clinical diagnoses of AD, so strict comparisons are hazardous. This does not imply that there are no genetic findings of very rare variants (f < 0.1%) still to be made, although the increasing predictability of genetic findings [8] [9] [10] [11] and the finding that most new findings relate to already identified pathways imply that research may be better focused on the targeted sequencing of established pathways, bioinformatic analyses of multiomic datasets, and cell biology rather than on large-scale genome-wide sequencing projects in unrelated sporadic AD individuals. These data also illustrate that there is a degree of misdiagnosis in the clinical AD series, 3 and even more so in population-based controls.
A final implication of these data is that genomewide genotyping and PRS-based analytic strategies are reasonably effective at predicting those who will develop disease. They also suggest that this predictive utility is unlikely to improve much more. This strategy may therefore now be useful for designing clinical trials and eventually in clinical practice.
